SWOG clinical trial number
CTSU/E1908

A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab

Closed
Phase
Published
Abbreviated Title
Phase II Alemttuzumab + Standard vs. Low Dose Rituximab for Elderly CLL
Activated
11/15/2010
Closed
10/31/2013
Participants
CTSU

Research committees

Leukemia

Treatment

Rituximab Campath-1H

Publication Information Expand/Collapse

2016

A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908)

C Zent;X Zang;RP Ketterling;C Hanson;E Libby;J Barrientos;T Call;J Call;JE Chang;JJ Liu;A Calvo;H Lazarus;J Rowe;S Luger;M Litzow;M Tallman American Journal of Hematology Mar;91(3):308-312

PMid: PMID26662208 | PMC number: PMC4806550

Other Clinical Trials

SWOG Clinical Trial Number
S2504

A Randomized Phase III Study of PIRtobrutinib plus R-CHOP vs. R-CHOP for Patients with Previously UntreateD RIchter TrAnsforMation (RT) (pirAMID)
Research Committee(s)
Leukemia
Lymphoma
Activated
06/01/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/A042302

Phase III Evaluation of Fixed Duration Zanubrutinib Plus Sonrotoclax-Based Therapy Compared to Continuous Zanubrutinib in Previously Untreated Older Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Research Committee(s)
Leukemia
Activated
03/06/2026
Open
Phase
SWOG Clinical Trial Number
S1925

A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.
Research Committee(s)
Leukemia
Lymphoma
Symptom Management and Survivorship
Activated
12/14/2020
Accrual
83%
Open
Phase